For
Period Ended:
|
October
31, 2009
|
o Transition Report on Form
10-K
|
|
o Transition Report on Form
20-F
|
|
o Transition Report on Form
11-K
|
|
o Transition Report on Form
10-Q
|
|
o Transition Report on Form
N-SAR
|
For
the Transaction Period
Ended:
|
October
31, 2009
|
Advanced
BioMedical Technologies, Inc.
|
Full
Name of Registrant
|
Former
Name if Applicable
|
18
Lake Ridge Dr.
|
Address
of Principal Executive Office (Street and Number)
|
Middletown,
NY 10940
|
City,
State and Zip Code
|
x
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense;
|
x
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or
before the fifteenth calendar day following the prescribed due date; or
the subject quarterly report of transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth calendar day following the
prescribed due date; and
|
o
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
SEC
1344 (03-05)
|
Persons who are to respond to
the collection of information contained in this form are not required
torespond unless
the form displays a currently valid OMB control
number.
|
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
|||||
Wang
Hui
|
718
|
766-7898
|
||||
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
||||
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed? If answer
is no, identify report(s).
|
|||||
x Yes
|
o No
|
|||||
(3)
|
Is
it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof?
|
|||||
o Yes
|
x No
|
|||||
If
so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
|
||||||
Advanced
BioMedical Technologies, Inc.
|
||||||
(Name
of Registrant as Specified in Charter)
|
||||||
has
caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
|
||||||
Date
|
February
1, 2010
|
By
|
/s/ Wang Hui /s/
|
|||
Wang
Hui
Chief
Executive Officer
|
||||||
ATTENTION
|
||
INTENTIONAL
MISSTATEMENTS OR OMISSIONS OF FACT
CONSTITUTE
FEDERAL CRIMINAL VIOLATIONS
(SEE
18 U.S.C. 1001)
|